Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
root beer for everyone !!
we are now .59 by .65 CRYO is looking good !!
we are now .59 by .65 CRYO is looking good !!
peterbel,
if this stock takes off, you buy the first round, i'll buy the second round...
yes it is... i was suggesting people buy it in the mid .20s last last September and now as mentioned just broke .70 and should go much higher in the future.. they have a GREAT technology !!
Did you have a chance to get into CRYO? or at least check it out?
CRYO just hit .70 !!
it looks like CRYO is starting to chew through the .64's
Call it what you want, just pointing out how cool 420cloud.com job search is for the industry !!
Just heard this interview of Former President of both EA and Activation and former Call of Duty and Tony Hawk developer, Mr. Danny Hammett. and Alex Mardikian from MCIG 420Cloud.com
Here is the link
http://www.cannabisradio.com/podcasts/420-cloud-cannabis-connection/how-advanced-technology-can-help-in-the-cannabis-industry/
just checked out the MCIG's 420cloud.com job search http://420jobsearch.com/
GREAT interview and very cool job site for people in or getting in the industry http://420jobsearch.com/
Im ready too !!
3 days till the 10k comes out !!
and another week has come and gone with no updates ....
Amazing technology
lookoveryourshoulder
nothing showed up on your post.
CRYO slowing moving up ....
Good call Bighdaddie !!
See highlighted comment by CEO John
American Cryostem Expands Acselerate Max(TM) Cell Culture Medium Patent Coverage
EATONTOWN, NJ / ACCESSWIRE / August 8, 2017 / American CryoStem Corporation (OTC PINK: CRYO), a leading developer and marketer of patented adipose tissue-based cellular technologies for the regenerative and personalized medicine industries with laboratories in New Jersey, Tokyo, Hong Kong and Shenzhen, China, today announced that it has expanded its patent coverage for its premier growth medium, ACSelerate MAXTM Mesenchymal Stem Cell Culture Medium.
ACSelerate MAX™ is an extension of our long-term plan to develop and implement a family of cell culture, lineage specific differentiation, transport and cryoprotectant mediums for use in the cellular biotech industry and specifically optimized to be used in conjunction with our patented ATGRAFTTM adipose tissue and ATCELLTM adipose derived stem cell technologies. The extremely rapid and robust growth of mesenchymal stem cells made possible by ACSelerateMAX™ is capable of supporting the creation of the large, individual patient cell lines necessary for autologous cell therapeutics.
The Company recently filed for patent protection for its premier growth medium, ACSelerate MAX™, in Europe, China, Hong Kong, Japan, Mexico, Thailand, Israel, Russia, India, Australia/New Zealand, Brazil, Canada, and Saudi Arabia. These international filings are part of the Company's aggressive intellectual property strategy and IP protection program that support its international licensing and domestic sales platform. ACSelerate MAX™ stem cell culture medium is currently manufactured and distributed domestically and internationally by PeproTech, a NJ based company manufacturing high quality cytokine products for the life-science and cell therapy markets, under its "PeproGrow" brand.
CRYO plans to continue to implement the licensing model developed for its ACSelerate MAXTM medium across its entire family of 14 growth and differentiation mediums and its line of transportation and cryopreservation mediums that are the subject of both issued and pending patents internationally.
John Arnone, Chairman and CEO of American CryoStem stated, "Our scientific team has worked tirelessly over the past several years to complete our full line of transport, culture and cryopreservation mediums to support our efforts to provide the highest quality autologous tissue and cellular products and services to our customers and to the industry." Arnone added, "To further our effort, American CryoStem plans to file a 510k registration with the FDA for ACSelerate MAX™ registration."
About American CryoStem Corporation
American CryoStem Corporation (OTC PINK: CRYO); was founded in 2008, and has evolved to become a biotechnology pioneer, standardizing adipose tissue derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, clinical laboratory in New Jersey and licensed laboratories in Hong Kong, China and Tokyo, Japan, operating on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue (fat) and adipose derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology which supports a growing pipeline of stem cell applications and biologic products. We are leveraging our proprietary, IRB approved, FDA compliant platform and a developed product portfolio to create a domestic and global footprint of licensed laboratory affiliates, physicians networks and research organizations who purchase tissue collection, processing and storage consumables from our Company. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC's) derived from adipose tissue that work in conjunction with our 13 patented (non-animal) medium lines. The Company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.
For more information, please visit: www.americancryostem.com and www.acslaboratories.com.
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
Contact:
info@americancryostem.com
SOURCE: American CryoStem Corporation
sure hope it runs into the teens very quickly...4 days and counting till 10k is due !!
Thank you peterbelt100... lets hope this move up quickly !!
10k is due before the Aug 15?
spread is tightening up
Very HUGE for CRYO and shareholders
yes we do !! hoping any day now.
MCIG Green again... and moving higher
http://www.otcmarkets.com/stock/CRYO/news
American Cryostem Expands Acselerate Max(TM) Cell Culture Medium Patent Coverage
EATONTOWN, NJ / ACCESSWIRE / August 8, 2017 / American CryoStem Corporation (OTC PINK: CRYO), a leading developer and marketer of patented adipose tissue-based cellular technologies for the regenerative and personalized medicine industries with laboratories in New Jersey, Tokyo, Hong Kong and Shenzhen, China, today announced that it has expanded its patent coverage for its premier growth medium, ACSelerate MAXTM Mesenchymal Stem Cell Culture Medium.
ACSelerate MAX™ is an extension of our long-term plan to develop and implement a family of cell culture, lineage specific differentiation, transport and cryoprotectant mediums for use in the cellular biotech industry and specifically optimized to be used in conjunction with our patented ATGRAFTTM adipose tissue and ATCELLTM adipose derived stem cell technologies. The extremely rapid and robust growth of mesenchymal stem cells made possible by ACSelerateMAX™ is capable of supporting the creation of the large, individual patient cell lines necessary for autologous cell therapeutics.
The Company recently filed for patent protection for its premier growth medium, ACSelerate MAX™, in Europe, China, Hong Kong, Japan, Mexico, Thailand, Israel, Russia, India, Australia/New Zealand, Brazil, Canada, and Saudi Arabia. These international filings are part of the Company's aggressive intellectual property strategy and IP protection program that support its international licensing and domestic sales platform. ACSelerate MAX™ stem cell culture medium is currently manufactured and distributed domestically and internationally by PeproTech, a NJ based company manufacturing high quality cytokine products for the life-science and cell therapy markets, under its "PeproGrow" brand.
CRYO plans to continue to implement the licensing model developed for its ACSelerate MAXTM medium across its entire family of 14 growth and differentiation mediums and its line of transportation and cryopreservation mediums that are the subject of both issued and pending patents internationally.
John Arnone, Chairman and CEO of American CryoStem stated, "Our scientific team has worked tirelessly over the past several years to complete our full line of transport, culture and cryopreservation mediums to support our efforts to provide the highest quality autologous tissue and cellular products and services to our customers and to the industry." Arnone added, "To further our effort, American CryoStem plans to file a 510k registration with the FDA for ACSelerate MAX™ registration."
About American CryoStem Corporation
American CryoStem Corporation (OTC PINK: CRYO); was founded in 2008, and has evolved to become a biotechnology pioneer, standardizing adipose tissue derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, clinical laboratory in New Jersey and licensed laboratories in Hong Kong, China and Tokyo, Japan, operating on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue (fat) and adipose derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology which supports a growing pipeline of stem cell applications and biologic products. We are leveraging our proprietary, IRB approved, FDA compliant platform and a developed product portfolio to create a domestic and global footprint of licensed laboratory affiliates, physicians networks and research organizations who purchase tissue collection, processing and storage consumables from our Company. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC's) derived from adipose tissue that work in conjunction with our 13 patented (non-animal) medium lines. The Company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.
For more information, please visit: www.americancryostem.com and www.acslaboratories.com.
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
Contact:
info@americancryostem.com
SOURCE: American CryoStem Corporation
© Copyright © 2017 Accesswire. All rights reserved.
MCIG is consolidating and should be moving hire in the future..
ENOUGH said !!
they posted the same on their fb... hope to hear something from them in the very near future... its time for this stock to go up !!
yes we do !! let me know your thoughts on the other 2 stocks..
hoping we get something soon !!
big block on the ask today at .61
Check out the news clip on MCIG's app 420cloud.com website centered around cannabis careers, and a local app that's getting buzz for helping you do good deeds.
https://www.facebook.com/nazyjavidnews/videos/280993525712649/
MCIG and 420Cloud.com starting to get traction in the Mj industry !!
as long as we're making money its all good... GLTU !!
lets hope it runs up and runs fast !!
Bids still lining up on CRYO !!
thank you wallstreet...
Apparently you haven't been watching the bid drop twice last week to .016 and rise back up to the .024 range..lol thats how much im paying attention..
MM's dont play games and try to shake out weak investors? thats your opinion and its hilarious !!
4life,
Check out CRYO and MCIG ...
Check out another Stem-cell company that is running on all cylinders..
check out the symbol CRYO, very small float and great team running this company..